TY - JOUR
T1 - Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study
AU - de Bruijn, Anne
AU - Schipper, Robert-Jan
AU - Voogd, Adri C.
AU - Pullens, Marleen J. J.
AU - Bloemen, Johanne G.
AU - de Munck, Linda
AU - van Riet, Yvonne E.
AU - Siesling, Sabine
AU - Vriens, Birgit E. P.
AU - Nieuwenhuijzen, Grard A. P.
PY - 2024/12/16
Y1 - 2024/12/16
N2 - Data are lacking on the optimal neoadjuvant systemic treatment of patients with hormone receptor and HER2 positive breast cancer who are unfit for the combination of chemotherapy and anti-HER2 therapy. A nationwide series of 190 breast cancer patients treated with neoadjuvant endocrine treatment (NET) or NET+anti-HER2 were evaluated. The ypT0 rate was significantly higher after NET+anti-HER2, with 10.0% (4/40) versus 1.3% (2/150) following NET (p = 0.019). The ypN0 rate was significantly higher after NET+anti-HER2, with 25.0% (6/24) versus 5.5% (3/55) following NET in cN+ patients (p = 0.020) and 81.3% (13/16) versus 55.8% (53/95) after NET in cN- patients (p = 0.047). In cN- patients, ypN0 status was independently associated with age (p = 0.008) and administration of NET+anti-HER2 (p = 0.016). These findings suggest a clinical benefit of treatment with NET+anti-HER2 if patients are unfit for the combination of anti-HER2 therapy with chemotherapy.
AB - Data are lacking on the optimal neoadjuvant systemic treatment of patients with hormone receptor and HER2 positive breast cancer who are unfit for the combination of chemotherapy and anti-HER2 therapy. A nationwide series of 190 breast cancer patients treated with neoadjuvant endocrine treatment (NET) or NET+anti-HER2 were evaluated. The ypT0 rate was significantly higher after NET+anti-HER2, with 10.0% (4/40) versus 1.3% (2/150) following NET (p = 0.019). The ypN0 rate was significantly higher after NET+anti-HER2, with 25.0% (6/24) versus 5.5% (3/55) following NET in cN+ patients (p = 0.020) and 81.3% (13/16) versus 55.8% (53/95) after NET in cN- patients (p = 0.047). In cN- patients, ypN0 status was independently associated with age (p = 0.008) and administration of NET+anti-HER2 (p = 0.016). These findings suggest a clinical benefit of treatment with NET+anti-HER2 if patients are unfit for the combination of anti-HER2 therapy with chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85213376929&partnerID=8YFLogxK
U2 - 10.3390/cancers16244188
DO - 10.3390/cancers16244188
M3 - Article
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 24
M1 - 4188
ER -
